Clinical significance of local control of primary tumour in definitive radiotherapy for scalp angiosarcomas. Issue 1 (20th November 2022)

• Record Type: Journal Article
• Authors: Kashihara, Tairo; Ogata, Dai; Okuma, Kae; Nakamura, Satoshi; Nakayama, Hiroki; Mori, Taisuke; Takahashi, Akira; Namikawa, Kenjiro; Takahashi, Ayaka; Takahashi, Kana; Kaneda, Tomoya; Inaba, Koji; Murakami, Naoya; Okamoto, Hiroyuki; Nakayama, Yuko; Yamazaki, Naoya; Igaki, Hiroshi
• Is Part Of: Skin research and technology. Volume 29:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-20
• Subjects: angiosarcoma -- intensity‐modulated radiotherapy -- radiotherapy -- skin neoplasms -- volumetric modulated‐arc therapy; Skin -- Research -- Periodicals; Skin -- Diseases -- Periodicals; Skin -- Physiology -- Periodicals; 616.5
• DOI: 10.1111/srt.13243
• Languages: English
• ISSNs: 0909-752X

Abstract

Abstract: Introduction: Scalp angiosarcoma is a rare and aggressive cancer. Definitive radiotherapy is a treatment option for localised scalp angiosarcoma patients. Although definitive surgical resection reportedly prolongs overall survival (OS), whether initial local treatment effect affects OS when definitive radiotherapy is administered is unclear. Therefore, this study analysed whether local recurrence within 6 months of irradiation correlates with OS and cancer‐specific survival (CSS). Furthermore, how local control affects patients' quality of life was investigated. Materials and methods: Thirty‐one localised scalp angiosarcoma patients who had received definitive radiotherapy at our institution between October 2010 and July 2021 were analysed retrospectively. The most commonly used dose fractionation was 70 Gy in 35 fractions (83.9%). Local recurrence within 6 months of radiotherapy and other clinical factors were examined in univariate and subsequent multivariate analyses for correlation with OS and CSS. Results: The median follow‐up period was 16 months (range, 6–45 months). Local recurrence was detected in 16 patients (51.6%), 12 of whom had recurrence within 6 months. In multivariate analyses, the presence of local recurrence within 6 months of radiotherapy was significantly associated with OS and CSS ( p = 0.003, 0.0001, respectively). Ten of the 16 patients with local recurrence had severe symptoms such as bleeding, pain, difficulty opening the eye and malodour. Conclusions: The initial local treatment effect was significantly associated with OS and CSS after definitive radiotherapy. Furthermore, local recurrence after radiotherapy resulted in a variety of symptoms, including bleeding and pain, which reduced the patient's quality of life.